Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2009-09-09

Last Posted Date: 2011-11-03

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 60

Registration Number: NCT00973882

Locations: 🇫🇷
Centre Val d'Aurelle, Montpellier, France
🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Centre François Baclesse, Caen, France

and more 8 locations

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Phase 2

Completed

Conditions: Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions: Drug: Bortezomib
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide

First Posted Date: 2009-08-27

Last Posted Date: 2020-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00967369

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2009-08-17

Last Posted Date: 2021-12-06

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 4

Registration Number: NCT00960297

Locations: 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Providence Medical Group, Terre Haute, Indiana, United States

and more 3 locations

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Large Cell Lung Carcinoma
Lung Adenocarcinoma
Stage IV Non-Small Cell Lung Cancer
Bronchioloalveolar Lung Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Biological: Cixutumumab
Drug: Paclitaxel

First Posted Date: 2009-08-10

Last Posted Date: 2018-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 175

Registration Number: NCT00955305

Locations: 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States

and more 161 locations

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 3

Conditions: Stage IA Uterine Sarcoma AJCC v7
Mixed Mesodermal (Mullerian) Tumor
Stage IA Ovarian Cancer AJCC v6 and v7
Stage IB Fallopian Tube Cancer AJCC v6 and v7
Stage IC Ovarian Cancer AJCC v6 and v7
Stage IIA Uterine Sarcoma AJCC v7
Stage IIC Fallopian Tube Cancer AJCC v6 and v7
Stage IIIA Ovarian Cancer AJCC v6 and v7
Stage IIIB Uterine Sarcoma AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Ifosfamide
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2009-08-07

Last Posted Date: 2021-09-30

Lead Sponsor: GOG Foundation

Target Recruit Count: 637

Registration Number: NCT00954174

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 532 locations

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Biological: Robatumumab
Biological: Trastuzumab
Drug: Carboplatin
Drug: Epirubicin
Drug: Everolimus
Drug: Gemcitabine
Biological: Cetuximab
Drug: 5-FU
Drug: Erlotinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Irinotecan
Drug: Folinic Acid

First Posted Date: 2009-08-07

Last Posted Date: 2018-08-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 15

Registration Number: NCT00954512

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Docetaxel
Drug: Carboplatin
Drug: Dexamethasone
Biological: EBV-specific cytotoxic T lymphocytes
Biological: G-CSF or Peg-GCSF

First Posted Date: 2009-08-06

Last Posted Date: 2017-08-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 20

Registration Number: NCT00953420

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Biological: dalotuzumab
Drug: gemcitabine hydrochloride

First Posted Date: 2009-08-04

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT00951444

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Stage III Ovarian Cancer AJCC v6 and v7
Stage IIIB Ovarian Cancer AJCC v6 and v7
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
Malignant Ovarian Brenner Tumor
Ovarian Seromucinous Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2009-08-04

Last Posted Date: 2021-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1560

Registration Number: NCT00951496

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 497 locations

Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: bevacizumab
Biological: trastuzumab
Drug: carboplatin
Drug: docetaxel
Other: laboratory biomarker analysis

First Posted Date: 2009-07-30

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT00949247

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals Monarch, Mayfield Heights, Ohio, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy